Você procurou por: meet the needs (Dinamarquês - Holandês)

the specific expertise and skills sought depend on the needs of the recruiting division .
the specific expertise and skills sought depend on the needs of the recruiting division .

existing human resources will be reallocated for the management and the needs of the programme , no other resources are necessary .
existing human resources will be reallocated for the management and the needs of the programme , no other resources are necessary .

we take the need to protect your data seriously .
we take the need to protect your data seriously .

in accordance with these points, eligible cost must be confined to the extra investment costs necessary to meet the environmental objectives.
in accordance with these points, eligible cost must be confined to the extra investment costs necessary to meet the environmental objectives.

titel på dokumentet points to consider on the need for assessment of reproductive toxicity of human insulin analogues
titel document points to consider on the need for assessment of reproductive toxicity of human insulin analogues

concept paper on the development of a cpmp points to consider on the need for reproduction toxicity studies in the development of human insulin analogues
reproduction toxicity studies in the development of human insulin analogues

konceptdokument immunotoxicity and the need to update the notes for guidance on repeat dose toxicity and on non - clinical local tolerance testing of medicinal products
concept-rapporten immunotoxicity and the need to update the notes for guidance on repeat dose toxicity and on non- clinical local tolerance testing of medicinal products

administrative expenditure not included in reference amount[11] the needs for human and administrative resources shall be covered within the allocation granted to the managing dg in the framework of the annual allocation procedure _bar_
administrative expenditure not included in reference amount[11] the needs for human and administrative resources shall be covered within the allocation granted to the managing dg in the framework of the annual allocation procedure _bar_

and / or ( b ) the participant no longer meets the access criteria laid down in article 4 .
and / or ( b ) the participant no longer meets the access criteria laid down in article 4 .

63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non- gmo containing medicinal products for human use non- clinical documentation of medicinal products with ‘ well- established use ’ note for guidance on the need for non- clinical testing of pharmaceuticals in juvenile animals discussion paper on the non- clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre- clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non- cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling
63) note for guidance on photosafety testing; points to consider document on the need for assessment of reproductive toxicity in the development of human insulin analogues discussion paper on environmental risk assessments of non-gmo containing medicinal products for human use non-clinical documentation of medicinal products with ‘ well-established use’ note for guidance on the need for non-clinical testing of pharmaceuticals in juvenile animals discussion paper on the non-clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre-clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non-cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling